Market Closed -
Other stock markets
|
After market 09:20:23 pm | |||
41.24 USD | +2.28% | 41.68 | +1.04% |
02:58pm | Bristol Myers: presents advances in lung cancer | CF |
02/06 | Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes | RE |
Sales 2024 * | 4.61TCr 3,82800Cr | Sales 2025 * | 4.61TCr 3,82600Cr | Capitalization | 8.33TCr 6,91900Cr |
---|---|---|---|---|---|
Net income 2024 * | -541.4Cr -45TCr | Net income 2025 * | 1.02TCr 85TCr | EV / Sales 2024 * | 2.65 x |
Net Debt 2024 * | 3.9TCr 3,24200Cr | Net Debt 2025 * | 3.17TCr 2,63100Cr | EV / Sales 2025 * | 2.5 x |
P/E ratio 2024 * |
-15.6
x | P/E ratio 2025 * |
7.77
x | Employees | 34,100 |
Yield 2024 * |
5.86% | Yield 2025 * |
6.15% | Free-Float | 69.27% |
Latest transcript on Bristol-Myers Squibb Company
1 day | +3.31% | ||
1 week | +1.57% | ||
Current month | +0.48% | ||
1 month | -5.90% | ||
3 months | -19.29% | ||
6 months | -17.74% | ||
Current year | -19.36% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 01/15/01 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 20/19/20 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 20/19/20 |
Peter Arduini
BRD | Director/Board Member | 59 | 01/16/01 |
Derica Rice
BRD | Director/Board Member | 59 | 01/20/01 |
Date | Price | Change | Volume |
---|---|---|---|
03/24/03 | 41.24 | +2.28% | 717 |
31/24/31 | 41.05 | +1.31% | 50,319 |
30/24/30 | 40.52 | +0.25% | 15,286 |
29/24/29 | 40.42 | -0.46% | 29,888 |
28/24/28 | 40.61 | -1.92% | 19,580 |
Delayed Quote London S.E., June 03, 2024 at 09:00 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.86% | 74TCr | |
+32.34% | 60TCr | |
-5.74% | 35TCr | |
+17.96% | 32TCr | |
+3.36% | 28TCr | |
+16.77% | 24TCr | |
+9.26% | 21TCr | |
-5.07% | 21TCr | |
+7.08% | 16TCr |
- Stock Market
- Equities
- BMY Stock
- 0R1F Stock